[1] Mcarthur, M.A. et al Molecular Characterization of Hamster-Adapted Yellow Fever Virus. Vector-B. Zoon. Dis. 20: 222–7. (2020).
[2] Gardner, C.L., Ryman, K.D. Yellow fever: a reemerging threat. (Special Issue: Emerging pathogens.). Clin. Lab. Med. 30: 237–60. https://doi.org/10.1016/j.cll.2010.01.001.(2010).
[3] Rice, C.M. et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229(4715): 726-33. doi: 10.1126/science.4023707 (1985).
[4] Chambers, T.J., McCourt, D.W., Rice, C.M. Production of yellow fever virus proteins in infected cells: Identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology 177:159–74. https://doi.org/10.1016/0042-6822(90)90470-C (1990).
[5] Ferreira, M.S. et al. Experimental yellow fever virus infection in the squirrel monkey (Saimiri spp.) I: Gross anatomical and histopathological findings in organs at necropsy. Mem. Inst. Oswaldo Cruz 115: 1–8. https://doi.org/10.1590/0074-02760190501 (2020).
[6] de Oliveira, G.M.M., Ferreira, R.M. Yellow fever and cardiovascular disease: An intersection of epidemics. Arq. Bras. Cardiologia 110: 207–10. https://doi.org/10.5935/abc.20180041 (2018).
[7] Lopes, R.L. et al. Kidney involvement in yellow fever: A review. Rev. Inst. Med. Trop. São Paulo 61: 1–11. https://doi.org/10.1590/s1678-9946201961035 (2019).
[8] Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Emergência epidemiológica de febre amarela no Brasil, no período de dezembro de 2016 a julho de 2017. Boletim Epidemiológico 48:1–22 (2017).
[9] Faria, N.R. etal. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science 361(6405):894-899. doi: 10.1126/science.aat7115 (2018).
[10] Giovanetti, M. et al. Yellow Fever Virus Reemergence and Spread in Southeast. J. Virology 94: e00375-20. doi: 10.1128/JVI.00375-20 (2020).
[11] Quaresma J.A. et al. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res. 116(1-2): 91-7. doi: 10.1016/j. virusres.2005.08.019 (2006).
[12] Quaresma, J.A. et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 345(1): 22-30. doi: 10.1016/j.virol.2005.09.058 (2006).
[13] Quaresma, J.A. et al. Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. ActaTropica 94(2): 116-27. doi: 10.1016/j.actatropica.2005.03.003 (2005).
[14] Quaresma, J.A., Pagliari, C., Medeiros, D.B., Duarte, M.I., Vasconcelos, P.F. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev. Med. Virology 5: 305-18. doi: 10.1002/rmv.1752, (2013).
[15] Monath, T.P. Yellow fever: An update. Lancet Infect. Dis. 1: 11–20. https://doi.org/10.1016/S1473-3099(01)00016-0 (2001).
[16] Patel, D.D., Kuchroo, V.K. Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. Immunity 43(6): 1040-51. doi: 10.1016/j.immuni.2015.12.003 (2015).
[17] Miossec, P., Kolls, J.K. Targeting IL-17 and T H 17 cells in chronic inflammation. Nat. Rev. Drug Discovery 11: 763–76https://doi.org/10.1038/nrd3794 (2012).
[18] Bystrom, J. et al. Functional and phenotypic heterogeneity of Th17 cells in health and disease. Eur. J. Clin. Investigation 49: 1–2. https://doi.org/10.1111/eci.13032 (2019).
[19] Li, Y. et al. The immunoregulation of Th17 in host against intracellular bacterial infection. Med. Inflammationhttps://doi.org/10.1155/2018/6587296 (2018).
[20] Azevedo, R.S.S. et al. In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus. Sci. Reports 8: 1–11. https://doi.org/10.1038/s41598-017-17765-5 (2018).
[21] Hernández-Santos, N., Gaffen, S.L. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11(5): 425-35. doi: 10.1016/j.chom.2012.04.008 (2012).
[22] Sánchez-Vargas, L.A. et al. Characterization of the IL-17 and CD4+ Th17 Cells in the Clinical Course of Dengue Virus Infections. Viruses 12(12): 1435. doi: 10.3390/v12121435 (2020).
[23] Shearer, F.M. et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect. Dis. 17: 1209–17. https://doi.org/10.1016/S1473-3099(17)30419-X (2017).
[24] Paules CI, Fauci AS. Yellow Fever - Once Again on the Radar Screen in the Americas. N. Engl. J. Med. 13; 376(15): 1397-9. doi: 10.1056/NEJMp1702172 (2017).
[25] Tranquilin, M.V. et al. First report of yellow fever virus in non-human primates in the State of Paraná, Brazil. Rev. Soc. Bras. Med. Trop.46: 522–4. https://doi.org/10.1590/0037-8682-0106-2013 (2013).
[26] Monath, T.P., Vasconcelos, P.F.C. Yellow fever. J. Clin. Virol. 64: 160–73. https://doi.org/10.1016/j.jcv.2014.08.030 (2015).
[27] Holanda, G.M. et al. Yellow fever virus modulates cytokine mRNA expression and induces activation of caspase 3/7 in the human hepatocarcinoma cell line HepG2. Arc. Virology 164: 1187–92. https://doi.org/10.1007/s00705-019-04171-7 (2019).
[28] Douam, F., Ploss, A. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe. Trends Microbiol. 26: 913–28. https://doi.org/10.1016/j.tim.2018.05.012 (2018).
[29] Walton, K.L., Johnson, K.E., Harrison, C.A. Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front. Pharmacol. 8. https://doi.org/10.3389/fphar.2017.00461(2017).
[30] Dong, X., Liu, J., Xu, Y., Cao, H. Role of macrophages in experimental liver injury and repair in mice (Review). Exp. Therap. Med. 3835–47. https://doi.org/10.3892/etm.2019.7450 (2019).
[31] Tacke, F., Zimmermann, H.W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatology 60: 1090–6. https://doi.org/10.1016/j.jhep.2013.12.025 (2014).
[32] Van der Heide, D., Weiskirchen, R., Bansal, R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front. Immunol. 10: 1–14. https://doi.org/10.3389/fimmu.2019.02852 (2019).
[33] Fabregat, I., Caballero-Díaz, D. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front. Oncol. 8. https://doi.org/10.3389/fonc.2018.00357, (2018).
[34] Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. novel insights into liver fibrosis. American Journal of Physiology - Cell Physiol. 305. https://doi.org/10.1152/ajpcell.00230.2013 (2013).
[35] Schmidt-Arras, D., Rose-John, S. IL-6 pathway in the liver: From physiopathology to therapy. J. Hepatology 64(6): 1403-15. doi: 10.1016/j.jhep.2016.02.004, (2016).
[36] Xu, R., Zhang, Z., Wang, F.S. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol. Immunol. 9(4): 296-301. doi: 10.1038/cmi.2011.53 (2012).
[37] Póvoa, T.F., et al. Peripheral organs of dengue fatal cases present strong pro-inflammatory response with participation of IFN-Gamma-, TNF-Alpha and RANTES-Producing cells. PLoS ONE 11: 1–19. https://doi.org/10.1371/journal.pone.0168973 (2016).
[38] Restrepo, B.N., et al. Serum levels of interleukin-6, tumor necrosis factor-alpha and interferon-gama in infants with and without dengue. Rev. Soc. Bras. Med. Trop. 41: 6–10. https://doi.org/10.1590/S0037-86822008000100002 (2008).
[39] Melo Iani, F.C., et al. Dengue patients with early hemorrhagic manifestations lose coordinate expression of the anti-inflammatory Cytokine Il-10 with the Inflammatory Cytokines IL-6 and IL-8. Am. J. Trop. Med. Hyg. 95: 193–200. https://doi.org/10.4269/ajtmh.15-0537 (2016).
[40] Chua, J.J., Bhuvanakantham, R., Chow, V.T., Ng, M.L. Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3 beta protein. Virus Res. 112(1-2): 85-94. doi: 10.1016/j.virusres.2005.03.025 (2005).
[41] Zeidler, J.D., Fernandes-Siqueira, L.O., Barbosa, G.M., Da Poian, A.T. Non-canonical roles of dengue virus non-structural proteins. Viruses 9. https://doi.org/10.3390/v9030042 (2017).
[42] Jain, A., Pandey, N., Garg, R.K., Kumar, R. IL-17 level in patients with dengue virus infection & its association with severity of illness. J. Clin. Immunol. 33: 613–8. https://doi.org/10.1007/s10875-012-9855-0 (2013).
[43] Guabiraba, R. et al. IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection. Eur. J. Immunol. 43: 1529–44. https://doi.org/10.1002/eji.201243229 (2013).
[44] McAleer, J.P., Kolls, J.K. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukocyte Biol. 90: 263–70. https://doi.org/10.1189/jlb.0211099 (2011).
[45] Zang, M. et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Bioch. Bioph. Acta – Mol. Basis Dis. 1864: 3759–70. https://doi.org/10.1016/j.bbadis.2018.10.004 (2018).